Alectinib Japan trial abstract

Abstract 9008 covers the J-ALEX phase 3 trial comparing Crizotinib (arm A) with Alectinib (arm B) in TKI naive patients. There were 207 patients at 41 centers in Japan randomized between the two arms.

Arm A had a median PFS of 10.2 months.

Arm B median PFS was not reached.

The trial was stopped early because an independent committee recommended the release of data because the superiority of PFS had been demonstrated.

there is another international trial ongoing.

This entry was posted in alectinib - Alecensa from Chugai - Roche - GenenTech, crizotinib - Xalkori from Pfizer, Lung cancer, Research, Resistance to treatment. Bookmark the permalink.

Leave a Reply